Emma Louise Robinson was born in North London, England and grew up in the nearby the home county of Hertfordshire. After her A-levels, Emma won a place to study Molecular & Cellular Biochemistry at Oxford University, where she was awarded a Nuffield scholarship for Academic Excellence.
After graduating from Oxford in 2010, Emma moved to the University of Cambridge where she was awarded a Wellcome Trust funded Master of Research (MRes) fellowship in Cardiovascular and Metabolic Disease. Having completed her MRes in 2011, Emma was granted a subsequent Wellcome Trust PhD fellowship to remain in Cambridge and carried out her PhD under the supervision of Prof. dr. LLewelyn Roderick at The Babraham Institute in Cambridge.In 2014, LLewelyn moved to KU Leuven, Belgium to join as Professor in the Laboratory of Experimental Cardiology alongside Prof. dr. Karin Sipido. Emma was fortunate to be able to also move to Leuven in 2015 thanks to an International scholarship from the KU Leuven Faculty of Medicine in order to complete her PhD research and thesis and obtain her PhD from the University of Cambridge.
Throughout her PhD years, Emma was heavily involved in a number of projects, including investigating the roles of non-coding RNAs, histone lysine methylation and DNA methylation in regulation of the transcriptome in cardiac ageing, hypertrophy and disease-associated remodelling.
In 2016, Emma was awarded a European Society of Cardiology First Contact Initiative grant to spend time as a visiting scientist in the laboratory of Prof. dr. Ivar Sjaastad at Oslo University, Norway. Here, she learnt from their expertise in in vivo modelling of cardiac disease and cardiac phenotyping in small rodents, alongside Dr. Magnus Aronsen.
In 2018, Emma joined the lab of Prof. dr. Stephane Heymans as a postdoctoral scientist, funded by the prestigious CVON Early HFPEF grant from the Netherlandse Hartstichting. In Maastricht, Emma’s research focus is on identifying novel biomarkers for early detection of heart failure with preserved ejection fraction and investigating novel mechanisms in the pathophysiology of this condition, for which commonly-used clinical biomarkers and treatments for heart failure are frequently ineffective.
Emma enjoys communicating science to the public and inspiring young people into a scientific career. She has been involved in a number of public engagement projects including organizing three Cambridge Science Festivals (UK) and has been an invited speaker at youth group and school career events. In 2016, Emma was invited to act as co-moderator at the Science Panel for Health workshop meetings at the European Commission and was involved in formulating final reports submitted to the Commission. She has a qualification in Public Engagement from the Medical Research Council (UK).